10 November 2017 EMA/PDCO/738440/2017 Inspections, Human Medicines Pharmacovigilance and Committees Division
Paediatric Committee (PDCO) Minutes of the meeting on 7-10 November 2017
Chair: Dirk Mentzer – Vice-Chair: Koenraad Norga 7 November 2017, 14:00- 19:00, room 3A 8 November 2017, 08:30- 19:00, room 3A 9 November 2017, 08:30- 19:00, room 3A 10 November 2017, 08:30- 13:00, room 3A Disclaimers Some of the information contained in this set of minutes is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the PDCO Committee meeting reports (after the PDCO Opinion is adopted), and on the Opinions and decisions on paediatric investigation plans webpage (after the EMA Decision is issued). Of note, this set of minutes is a working document primarily designed for PDCO members and the work the Committee undertakes. Further information with relevant explanatory notes can be found at the end of this document. Note on access to documents Some documents mentioned in the minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to ongoing procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact
An agency of the European Union
© European Medicines Agency, 2017. Reproduction is authorised provided the source is acknowledged.
Table of contents 1.
Introductions
1.1.
Welcome and declarations of interest of members, alternates and experts ............ 8
1.2.
Adoption of agenda ................................................................................................ 8
1.3.
Adoption of the minutes ......................................................................................... 8
2.
Opinions
2.1.
Opinions on Products .............................................................................................. 8
2.1.1.
Brazikumab - EMEA-001929-PIP01-16 ......................................................................... 8
2.1.2.
Susoctocog alfa - EMEA-000753-PIP02-16 .................................................................... 9
2.1.3.
Risankizumab - EMEA-001776-PIP02-17 ....................................................................... 9
2.1.4.
Trazodone hydrochloride - EMEA-002142-PIP01-17 ....................................................... 9
2.1.5.
Carotuximab - Orphan - EMEA-002138-PIP01-17 ........................................................... 9
2.1.6.
fully human monoclonal antibody (mAb) directed against the human PD-1 receptor - EMEA002007-PIP02-17 .................................................................................................... 10
2.1.7.
Vosoritide - Orphan - EMEA-002033-PIP01-16............................................................. 10
2.1.8.
Formoterol fumarate / glycopyrronium bromide / budesonide - EMEA-002063-PIP01-16... 10
2.1.9.
Synthetic double-stranded small interfering RNA (siRNA) oligonucleotide specific to the mRNA of the caspase 2 gene - EMEA-002224-PIP01-17 ......................................................... 11
2.1.10.
Sirolimus - Orphan - EMEA-002213-PIP01-17.............................................................. 11
2.2.
Opinions on Compliance Check ............................................................................. 12
2.2.1.
Fingolimod (hydrochloride) - EMEA-C-000087-PIP01-07-M05 ........................................ 12
2.2.2.
L-Asparaginase encapsulated in Erythrocytes - EMEA-C2-000341-PIP02-09-M04 ............. 12
2.2.3.
Cytarabine (liposomal combination) / Daunorubicin (liposomal combination) - EMEA-C1001858-PIP02-16-M01 ............................................................................................. 12
2.2.4.
Recombinant human nerve growth factor - EMEA-C-001729-PIP01-14-M01 .................... 13
2.2.5.
Avacopan - EMEA-C1-002023-PIP01-16-M01 .............................................................. 13
2.2.6.
Mepolizumab - EMEA-C-000069-PIP02-10-M08 ........................................................... 13
2.2.7.
Influenza virus surface antigens (haemagglutinin and neuraminidase) of the following strains: A/(H1N1), A/(H3N2), B/Yamagata lineage, B/Victoria lineage based on annual recommendations by WHO, CHMP (EU) and other regional or local authorities - EMEA-C1-001782-PIP01-15 .............................. 14
2.2.8.
Galcanezumab - EMEA-C3-001860-PIP03-16 – POSTPONED TO DECEMBER .................... 14
2.3.
Opinions on Modification of an Agreed Paediatric Investigation Plan ................... 14
2.3.1.
Recombinant human glutamic acid decarboxylase (rhGAD65) - EMEA-000609-PIP01-09-M0114
2.3.2.
Eluxadoline - EMEA-001579-PIP01-13-M02 ................................................................. 14
2.3.3.
Human coagulation factor X - Orphan - EMEA-000971-PIP01-10-M03 ............................ 15
2.3.4.
Avacopan - Orphan - EMEA-002023-PIP01-16-M02 ...................................................... 15
2.3.5.
Human normal immunoglobulin for subcutaneous administration - EMEA-001853-PIP01-15M01 ....................................................................................................................... 15
Paediatric Committee (PDCO) EMA/PDCO/738440/2017
8
8
Page 2/43
2.3.6.
Bezlotoxumab - EMEA-001645-PIP01-14-M02 ............................................................. 16
2.3.7.
Ataluren - Orphan - EMEA-000115-PIP01-07-M09........................................................ 16
2.3.8.
Delta-9-tetrahydrocannabinol / Cannabidiol - EMEA-000181-PIP01-08-M04 .................... 17
2.3.9.
Blinatumomab - Orphan - EMEA-000574-PIP02-12-M02 ............................................... 17
2.3.10.
Ibrutinib - Orphan - EMEA-001397-PIP03-14-M03 ....................................................... 17
2.3.11.
Inotuzumb ozogamicin - Orphan - EMEA-001429-PIP01-13-M02.................................... 18
2.3.12.
Human Thrombin / Human Fibrinogen - EMEA-001149-PIP01-11-M04 ............................ 18
2.3.13.
Lanadelumab - Orphan - EMEA-001864-PIP01-15-M01 ................................................. 18
2.3.14.
Sildenafil - Orphan - EMEA-000671-PIP01-09-M09....................................................... 19
2.3.15.
Aluminium hydroxide adsorbed, depigmented glutaraldehyde polymerised, allergen extract of Phleum pratense, Dactylis glomerata, Festuca elatior, Lolium perenne and Poa pratensis pollen (Grasses-Mix) (1/5) each - EMEA-000794-PIP01-09-M01 ............................................. 19
2.3.16.
Aluminium hydroxide adsorbed, depigmented glutaraldehyde polymerised, allergen extract of Phleum pratense, Dactylis glomerata, Festuca elatior, Lolium perenne and Poa pratensis pollen (Grasses-Mix) and Secale cereale (Cultivated Rye) pollen (50/50) - EMEA-000792-PIP01-09M01 ....................................................................................................................... 20
2.3.17.
Aluminium hydroxide adsorbed, depigmented glutaraldehyde polymerised, allergic extract of Phleum pratense pollen - EMEA-000795-PIP01-09-M01 ................................................ 20
2.4.
Opinions on Re-examinations ............................................................................... 21
2.4.1.
Crisaborole - EMEA-002065-PIP01-16 ........................................................................ 21
2.5.
Finalisation and adoption of opinions ................................................................... 21
3.
Discussion of applications
3.1.
Discussions on Products D90-D60-D30 ................................................................. 21
3.1.1.
Chloroprocaine Hydrochloride - EMEA-000639-PIP03-16 ............................................... 21
3.1.2.
Lucerastat - Orphan - EMEA-002095-PIP01-16 ............................................................ 21
3.1.3.
EMEA-002109-PIP01-16 ........................................................................................... 21
3.1.4.
Maralixibat Chloride - Orphan - EMEA-001475-PIP03-17 ............................................... 22
3.1.5.
Glutamine (Levoglutamide) - Orphan - EMEA-001996-PIP02-16 .................................... 22
3.1.6.
Upadacitinib - EMEA-001741-PIP02-16 ...................................................................... 22
3.1.7.
Obiltoxaximab - EMEA-002144-PIP01-17 .................................................................... 22
3.1.8.
Gilteritinib (as fumarate) - EMEA-002064-PIP01-16 ..................................................... 22
3.1.9.
Recombinant Clostridium difficile Toxoid B / Recombinant Clostridium difficile Toxoid A - EMEA002112-PIP01-16 .................................................................................................... 22
3.1.10.
EMEA-001527-PIP02-17 ........................................................................................... 23
3.1.11.
Itacitinib - EMEA-002178-PIP01-17 ............................................................................ 23
3.1.12.
Fremanezumab - EMEA-001877-PIP03-17 .................................................................. 23
3.1.13.
Setmelanotide - Orphan - EMEA-002209-PIP01-17 ...................................................... 23
3.1.14.
Afatinib - EMEA-001596-PIP02-17 ............................................................................. 23
3.1.15.
Fosnetupitant / palonosetron - EMEA-001198-PIP03-17................................................ 24
3.1.16.
EMEA-002160-PIP01-17 ........................................................................................... 24
Paediatric Committee (PDCO) EMA/PDCO/738440/2017
21
Page 3/43
3.1.17.
Clade C gp140 - EMEA-002221-PIP01-17.................................................................... 24
3.1.18.
Mosaic gp140 / Clade C gp140 - EMEA-002161-PIP01-17 ............................................. 24
3.1.19.
Rosuvastatin calcium / Acetylsalicylic acid - EMEA-002239-PIP01-17 ............................. 24
3.1.20.
Baricitinib - EMEA-001220-PIP03-16 .......................................................................... 24
3.1.21.
Fluorocholine (18F) - EMEA-002129-PIP02-17 ............................................................. 25
3.1.22.
Bis-choline tetrathiomolybdate - Orphan - EMEA-002232-PIP01-17 ................................ 25
3.1.23.
Ethinyl estradiol / Dienogest - EMEA-002229-PIP01-17 ................................................ 25
3.1.24.
Semaglutide - EMEA-001441-PIP03-17....................................................................... 25
3.1.25.
Orphan - EMEA-002233-PIP01-17 .............................................................................. 25
3.1.26.
Amiselimod - EMEA-002227-PIP01-17 ........................................................................ 25
3.1.27.
Ustekinumab - EMEA-000311-PIP05-17 ...................................................................... 25
3.1.28.
(6aR,10aR)-1-Hydroxy-6,6-dimethyl-3-(2-methyl-2-octanyl)-6a,7,10,10a-tetrahydro-6Hbenzo[c]chromene-9-carboxylic acid - Orphan - EMEA-002069-PIP02-17 ....................... 26
3.1.29.
Riociguat - Orphan - EMEA-000718-PIP03-17 .............................................................. 26
3.1.30.
The whole range of unmanipulated autologous mononuclear cells derived from human umbilical cord blood (Hau-UCB-mnc) - Orphan - EMEA-001799-PIP02-17 ....................... 26
3.1.31.
Vatiquinone - Orphan - EMEA-002235-PIP01-17 .......................................................... 26
3.1.32.
Tucatinib - EMEA-002242-PIP01-17 ........................................................................... 26
3.1.33.
Recombinant human epidermal growth factor - EMEA-002258-PIP01-17......................... 26
3.1.34.
Human donor hematopoietic stem and progenitor cells (HSPC) that have been treated ex vivo with Tat-MYC fusion protein - Orphan - EMEA-002185-PIP02-17 ................................... 27
3.1.35.
Purified Rabies virus - EMEA-002234-PIP01-17............................................................ 27
3.2.
Discussions on Compliance Check......................................................................... 27
3.2.1.
Clostridium Botulinum neurotoxin type A (150 kD) - EMEA-C-001039-PIP01-10-M02 ....... 27
3.2.2.
Clostridium Botulinum neurotoxin type A (150 kD) - EMEA-C1-001039-PIP02-12-M02 ..... 27
3.2.3.
Japanese-encephalitis virus, inactivated - EMEA-C-000559-PIP01-09-M04 ..................... 27
3.3.
Discussions on Modification of an Agreed Paediatric Investigation Plan............... 28
3.3.1.
Regadenoson - EMEA-000410-PIP01-08-M02 .............................................................. 28
3.3.2.
Gadolinium,[α3,α6,α9-tris[3-[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-3-oxopropyl]3,6,9,15-tetraazabicyclo[9.3.1]pentadeca-1(15),11,13-triene-3,6,9-triacetato(3-)κN3,κN6,κN9,κN15,κO3,κO6,κO9] - EMEA-001949-PIP01-16-M01 ................................. 28
3.3.3.
Empagliflozin - EMEA-000828-PIP01-09-M06 .............................................................. 28
3.3.4.
Linagliptin (as base) - EMEA-000498-PIP01-08-M07 .................................................... 28
3.3.5.
Sitagliptin phosphate - EMEA-000470-PIP01-08-M10 ................................................... 28
3.3.6.
Baricitinib - EMEA-001220-PIP01-11-M02 ................................................................... 28
3.3.7.
Human normal immunoglobulin - EMEA-001797-PIP01-15-M01 ..................................... 29
3.3.8.
Ixekizumab - EMEA-001050-PIP01-10-M03 ................................................................. 29
3.3.9.
Tofacitinib - EMEA-000576-PIP01-09-M08 .................................................................. 29
3.3.10.
Ustekinumab - EMEA-000311-PIP03-11-M03............................................................... 29
3.3.11.
Ceftaroline fosamil - EMEA-000769-PIP01-09-M07 ...................................................... 29
Paediatric Committee (PDCO) EMA/PDCO/738440/2017
Page 4/43
3.3.12.
Cobicistat / atazanavir sulphate - EMEA-001465-PIP01-13-M02..................................... 30
3.3.13.
Oseltamivir phosphate - EMEA-000365-PIP01-08-M09 ................................................. 30
3.3.14.
Posaconazole - EMEA-000468-PIP02-12-M04 .............................................................. 30
3.3.15.
Tedizolid phosphate - EMEA-001379-PIP01-12-M03 ..................................................... 30
3.3.16.
Tenofovir alafenamide - EMEA-001584-PIP01-13-M03 .................................................. 31
3.3.17.
Lacosamide - EMEA-000402-PIP02-11-M05................................................................. 31
3.3.18.
Midostaurin - Orphan - EMEA-000780-PIP01-09-M04 ................................................... 31
3.3.19.
Pembrolizumab - EMEA-001474-PIP02-16-M01 ........................................................... 31
3.3.20.
Burosumab; Human recombinant IgG1 monoclonal antibody to fibroblast growth factor 23 (FGF23); - Orphan - EMEA-001659-PIP01-15-M03 ...................................................... 31
3.3.21.
Conestat alfa - EMEA-000367-PIP01-08-M07 .............................................................. 32
3.3.22.
Ivacaftor / lumacaftor - EMEA-001582-PIP01-13-M07 .................................................. 32
3.3.23.
Matrix applied characterised autologous cultured chondrocytes - EMEA-000979-PIP01-10-M02 ............................................................................................................................. 32
3.3.24.
Birch pollen extract (Betula verrucosa) - EMEA-001879-PIP01-15-M01 ........................... 32
3.3.25.
Reslizumab - EMEA-001202-PIP02-13-M02 ................................................................. 32
3.3.26.
N-[(1,3-dicyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine EMEA-001452-PIP01-13-M01 .................................................................................... 32
3.3.27.
Outer Membrane Vescicles (OMV) from Neisseria Meningitidis serogroup B strain NZ98/254 measured as amount of total protein containing the PorA P1.4 / Recombinant Neisseria Meningitidis serogroup B fHbp fusion protein / Recombinant Neisseria Meningitidis serogroup B NadA protein / Recombinant Neisseria Meningitidis serogroup B NHBA fusion protein - EMEA000139-PIP01-07-M02 ............................................................................................. 33
4.
Nominations
4.1.
List of letters of intent received for submission of applications with start of procedure 23 January 2018 for Nomination of Rapporteur and Peer reviewer ..... 33
4.2.
Nomination of Rapporteur for requests of confirmation on the applicability of the EMA decision on class waiver. .............................................................................. 33
4.3.
Nominations for other activities ........................................................................... 33
5.
Scientific Advice Working Party (SAWP) and Paediatric Committee (PDCO) Interaction 33
6.
Discussion on the applicability of class waivers
6.1.
Discussions on the applicability of class waiver for products................................ 34
7.
Discussion on the inclusion of an indication within a condition in an agreed PIP/waiver 34
7.1.
Discussion on the possibility to include an indication within a condition in an agreed PIP/waiver ........................................................................................................... 34
7.1.1.
Rivaroxaban - EMEA-000430-PIP01-08-M10 ............................................................... 34
Paediatric Committee (PDCO) EMA/PDCO/738440/2017
33
33
Page 5/43
8.
Annual reports on deferrals
34
9.
Organisational, regulatory and methodological matters
34
9.1.
Mandate and organisation of the PDCO................................................................. 34
9.1.1.
User manual on CxMP/EMA external representation ..................................................... 34
9.2.
Coordination with EMA Scientific Committees or CMDh-v ..................................... 34
9.2.1.
Committee for Medicinal Products for Human Use (CHMP) ............................................ 34
9.2.2.
CHMP Oncology Working Party Workshop on: Histology – independent indications in Oncology ............................................................................................................................. 35
9.2.3.
CHMP-PDCO common session.................................................................................... 35
9.2.4.
Questions from PRAC to PDCO following a MS request for PRAC Advice .......................... 35
9.3.
Coordination with EMA Working Parties/Working Groups/Drafting Groups ......... 35
9.3.1.
Non-clinical Working Group: D30 Products identified .................................................... 35
9.3.2.
Non-clinical Working Group: Call for additional members .............................................. 35
9.3.3.
Formulation Working Group ...................................................................................... 35
9.3.4.
Formulation Working Group: PDCO FWG participants 2018 ........................................... 36
9.3.5.
Guideline on the development of new medicinal products for the treatment of Crohn’s Disease and ulcerative colitis – POSTPONED TO DECEMBER ...................................................... 36
9.3.6.
Guideline on the clinical evaluation of vaccines ............................................................ 36
9.3.7.
Minutes of the PCWP/HCPWP joint meeting held on 20 September 2017 ......................... 36
9.3.8.
FDA Public Workshop- Advancing the Development of Pediatric Therapeutics (ADEPT) Application of "Big Data" to Pediatric Safety Studies - Report from the meeting ............... 36
9.4.
Cooperation within the EU regulatory network ..................................................... 36
9.4.1.
European Network of Paediatric Research (Enpr) - European Medicines Agency (EMA) ...... 36
9.4.2.
European Commission .............................................................................................. 37
9.5.
Cooperation with International Regulators........................................................... 37
9.6.
Contacts of the PDCO with external parties and interaction with the Interested Parties to the Committee ...................................................................................... 37
9.7.
PDCO work plan .................................................................................................... 37
9.7.1.
Draft PDCO Work plan 2018 ...................................................................................... 37
9.8.
Planning and reporting ......................................................................................... 37
9.8.1.
Report on the PDCO Strategic Review & Learning meeting in Tallinn, 4-6 October 2017.... 37
10.
Any other business
10.1.
AOB topic .............................................................................................................. 38
11.
Breakout sessions
11.1.1.
Paediatric oncology .................................................................................................. 38
11.1.2.
Neonatology ........................................................................................................... 38
11.1.3.
Inventory ............................................................................................................... 38
Paediatric Committee (PDCO) EMA/PDCO/738440/2017
38
38
Page 6/43
12.
List of participants
39
13.
Explanatory notes
43
Paediatric Committee (PDCO) EMA/PDCO/738440/2017
Page 7/43
1.
Introductions
1.1.
Welcome and declarations of interest of members, alternates and experts In accordance with the Agency’s policy on handling of declarations of interests of scientific committees’ members and experts, based on the declarations of interest submitted by the Committee members, alternates and experts and based on the topics in the agenda of the current meeting, the Committee Secretariat announced the restricted involvement of some meeting participants in upcoming discussions as included in the pre-meeting list of participants and restrictions. Participants in this meeting were asked to declare any changes, omissions or errors to their declared interests and/or additional restrictions concerning the matters for discussion. No new or additional interests or restrictions were declared. Discussions, deliberations and voting took place in full respect of the restricted involvement of Committee members and experts in line with the relevant provisions of the Rules of Procedure and as included in the list of participants. All decisions taken at this meeting were made in the presence of a quorum of members (i.e. 23 or more members were present in the room). All decisions, recommendations and advice were agreed by consensus, unless otherwise specified.
1.2.
Adoption of agenda The agenda was adopted with amendments.
1.3.
Adoption of the minutes The minutes of the October 2017 PDCO plenary meeting were adopted with amendments and will be published on the EMA website.
2.
Opinions
Disclosure of some information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.
2.1.
Opinions on Products
2.1.1.
Brazikumab - EMEA-001929-PIP01-16 Allergan Limited; Crohn's disease, Ulcerative colitis Day 120 opinion Gastroenterology-Hepatology
Paediatric Committee (PDCO) EMA/PDCO/738440/2017
Page 8/43
Summary of committee discussion: A positive opinion was adopted on D120.
2.1.2.
Susoctocog alfa - EMEA-000753-PIP02-16 Baxalta Innovations GmbH; Congenital haemophilia A with antibodies (inhibitors) to human factor VIII / Peri-operative management in patients with congenital haemophilia A with antibodies (inhibitors) to human FVIII Day 120 opinion Haematology-Hemostaseology Summary of committee discussion: Based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO agrees with the applicant's responses to D90 outstanding issues and therefore a positive opinion was adopted.
2.1.3.
Risankizumab - EMEA-001776-PIP02-17 AbbVie Ltd; Chronic Idiopathic Arthritis Day 120 opinion Immunology-Rheumatology-Transplantation Summary of committee discussion: The PDCO confirmed the outcome of the Day 90 discussion. Moreover, the committee received clarification which was deemed agreeable. A positive opinion was adopted.
2.1.4.
Trazodone hydrochloride - EMEA-002142-PIP01-17 Aziende Chimiche Riunite Angelini Francesco - A.C.R.A.F - S.p.A; Treatment of insomnia Day 120 opinion Neurology Summary of committee discussion: The Committee re-discussed the application including the additional information received since Day 90 and concluded that all issues have now been resolved, the PIP is approvable. A positive opinion was adopted.
2.1.5.
Carotuximab - Orphan - EMEA-002138-PIP01-17 TRACON Pharma Limited; Treatment of soft tissue sarcoma Day 120 opinion Oncology
Paediatric Committee (PDCO) EMA/PDCO/738440/2017
Page 9/43
Summary of committee discussion: Following the Day 30 discussion a draft opinion was shared with the applicant and an agreement was reached on the last few outstanding issues. Thus, the PDCO adopted a positive opinion on the paediatric plan proposed by the applicant.
2.1.6.
fully human monoclonal antibody (mAb) directed against the human PD-1 receptor - EMEA-002007-PIP02-17 Regeneron Ireland U.C.; Treatment of all conditions included in the category of malignant neoplasms (except haematopoietic and lymphoid tissue) / Treatment of newly diagnosed diffuse intrinsic pontine gliomas (DIPG), newly diagnosed and recurrent high-grade gliomas (HGG) Day 120 opinion Oncology Summary of committee discussion: The PDCO re-discussed the application for cemiplimab also taking into account the clarifications received after D90 and the applicant’s comments on the draft opinion. In conclusion, the PDCO recommends granting a paediatric investigation plan for cemiplimab for the entire paediatric population (from birth to less than 18 years of age) and a deferral.
2.1.7.
Vosoritide - Orphan - EMEA-002033-PIP01-16 BioMarin International Limited; Treatment of achondroplasia Day 120 opinion Other Summary of committee discussion: Considering the new information received after day 90 all issues are resolved. Taking the above into account a positive opinion endorsing the PIP has been adopted.
2.1.8.
Formoterol fumarate / glycopyrronium bromide / budesonide - EMEA-002063PIP01-16 Pearl Therapeutics, Inc.; Asthma / For the regular treatment of asthma in children 6 to 11 years of age where use of a triple combination medicinal product (ICS, LAMA and LABA) is appropriate: • patients not adequately controlled with ICS and another controller such as a LABA or LAMA Day 120 opinion Pneumology - Allergology Summary of committee discussion:
Paediatric Committee (PDCO) EMA/PDCO/738440/2017
Page 10/43
The PDCO discussed this procedure on D120. The applicant’s responses to the D90 issues were acknowledged. All issues were resolved and a positive opinion was adopted.
2.1.9.
Synthetic double-stranded small interfering RNA (siRNA) oligonucleotide specific to the mRNA of the caspase 2 gene - EMEA-002224-PIP01-17 Quark Pharmaceuticals, Inc.; Treatment of optic nerve bleeding and vascular disorders / Treatment of ischaemic optic neuropathy Day 60 opinion Ophthalmology Summary of committee discussion: A positive opinion was adopted on D60. Based on the assessment of this application and discussions at the Paediatric Committee, the PDCO agrees with the applicant's request for a waiver. The PDCO recommends granting a waiver for Synthetic double-stranded small interfering RNA (siRNA) oligonucleotide specific to the mRNA of the caspase 2 gene for all subsets of the paediatric population (0 to 18 years of age) in the condition of Treatment of optic ischaemic neuropathy. The PDCO emphasises that the granting of a waiver for the condition mentioned above should not prevent the applicant from considering a development in the paediatric population in indications where there is a paediatric need. In principle according to the Paediatric Regulation, incentives for the development for use in the paediatric population are available even if a waiver has been granted in another condition.
2.1.10.
Sirolimus - Orphan - EMEA-002213-PIP01-17 Vascular Therapies, Inc.; Prevention of arteriovenous access dysfunction Day 60 opinion Other Summary of committee discussion: The PDCO confirmed the outcome of the discussion of Day 30 and agreed with a full waiver based on lack of significant therapeutic benefit for all paediatric age groups in the condition “prevention of arteriovenous access dysfunction”. Based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO agrees with the applicant's request for a waiver. The PDCO recommends granting a waiver for Sirolimus for all subsets of the paediatric population (0 to less than 18 years of age) in the condition of Prevention of arteriovenous access dysfunction. The PDCO emphasises that the granting of a waiver for the condition mentioned above should not prevent the applicant from considering a development in the paediatric population in indications where there is a paediatric need.
Paediatric Committee (PDCO) EMA/PDCO/738440/2017
Page 11/43
2.2.
Opinions on Compliance Check The following compliance checks have been put up for discussion and the members of the PDCO have been invited to comment on issues of possible non-compliance
2.2.1.
Fingolimod (hydrochloride) - EMEA-C-000087-PIP01-07-M05 Novartis Europharm Limited; Treatment of Multiple Sclerosis Day 30 opinion Neurology Summary of committee discussion: The PDCO adopted on 10 November 2017 an opinion confirming the compliance of all studies in the agreed paediatric investigation plan as set out in the latest Agency's Decision (P/0050/2017) of 03 April 2017.
2.2.2.
L-Asparaginase encapsulated in Erythrocytes - EMEA-C2-000341-PIP02-09-M04 ERYTECH Pharma S.A.; Treatment of Acute Lymphoblastic Leukaemia Day 30 letter Oncology Summary of committee discussion: The PDCO discussed the compliance check for the completed Study. The PDCO therefore concluded that Study was not compliant with the latest Agency's Decision (P/0267/2017) of 4 September 2017.
2.2.3.
Cytarabine (liposomal combination) / Daunorubicin (liposomal combination) EMEA-C1-001858-PIP02-16-M01 Jazz Pharmaceuticals Ireland Limited; Treatment of acute myeloid leukaemia Day 30 letter Oncology Summary of committee discussion: The PDCO discussed the compliance request on 10 November 2017. The PDCO confirmed that the studies were compliant with the latest Agency's Decision (P/0299/2017) of 04 October 2017. The PDCO finalised on 10 November 2017 this partially completed compliance procedure and confirmed the compliance of all those studies contained in the agreed paediatric investigation plan that were to be completed until this date.
Paediatric Committee (PDCO) EMA/PDCO/738440/2017
Page 12/43
2.2.4.
Recombinant human nerve growth factor - EMEA-C-001729-PIP01-14-M01 Dompé farmaceutici SpA; Treatment of neurotrophic keratitis Day 30 Opinion Ophthalmology Summary of committee discussion: The PDCO discussed the completed studies and considered that these are compliant with the latest Agency's Decision. The PDCO adopted an opinion confirming the compliance of all studies in the agreed paediatric investigation plan as set out in the latest Agency's Decision.
2.2.5.
Avacopan - EMEA-C1-002023-PIP01-16-M01 ChemoCentryx, Ltd.; Treatment of antineutrophil cytoplasmic antibody (ANCA)associated vasculitis Day 60 letter Immunology-Rheumatology-Transplantation Summary of committee discussion: The PDCO discussed the completed Studies and considered that these are not compliant with the latest Agency's Decision (P/0268/2017) of 7 September 2017. The PDCO finalised on 8 November 2017 this partially completed compliance procedure.
2.2.6.
Mepolizumab - EMEA-C-000069-PIP02-10-M08 GSK TRADING SERVICES LIMITED; Treatment of asthma Day 60 opinion Pneumology - Allergology Summary of committee discussion: The PDCO took note of preceding procedures and reports on partially completed compliance (EMEA-C1-000069-PIP02-10-M02 and EMEA-C2-000069-PIP02-10-M04). The PDCO adopted on 10 November 2017 an opinion confirming the compliance of all studies in the agreed paediatric investigation plan as set out in the latest Agency's Decision (P/0239/2017) of 11 August 2017.
Paediatric Committee (PDCO) EMA/PDCO/738440/2017
Page 13/43
2.2.7.
Influenza virus surface antigens (haemagglutinin and neuraminidase) of the following strains: A/(H1N1), A/(H3N2), B/Yamagata lineage, B/Victoria lineage based on annual recommendations by WHO, CHMP (EU) and other regional or local authorities EMEA-C1-001782-PIP01-15 Abbott Biologicals B.V.; Prevention of influenza infection Day 30 letter Vaccines Summary of committee discussion: The completed study was checked for compliance The PDCO discussed the completed study and considered that this is not compliant with the latest Agency's Decision (P/0182/2015) of 07 August 2015.
2.2.8.
Galcanezumab - EMEA-C3-001860-PIP03-16 – POSTPONED TO DECEMBER Eli Lilly Nederland B.V.; Prevention of migraine headaches Day 1 letter Neurology
2.3.
Opinions on Modification of an Agreed Paediatric Investigation Plan
2.3.1.
Recombinant human glutamic acid decarboxylase (rhGAD65) - EMEA-000609PIP01-09-M01 Diamyd Medical AB; E10 Insulin-dependent diabetes mellitus / Treatment of type 1 Diabetes Mellitus of recent onset Day 60 opinion Endocrinology-Gynaecology-Fertility-Metabolism Summary of committee discussion: The Applicant has submitted answers to the questions forwarded by the PDCO. Based on the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan, and the answers to the questions submitted, the PDCO considered that the proposed changes cannot be accepted. The PDCO therefore adopted a negative Opinion on the request of modification of the agreed PIP as set in the Agency’s latest decision (P/167/2010).
2.3.2.
Eluxadoline - EMEA-001579-PIP01-13-M02 Allergan Limited; Irritable bowel syndrome with diarrhoea
Paediatric Committee (PDCO) EMA/PDCO/738440/2017
Page 14/43
Day 60 opinion Gastroenterology-Hepatology Summary of committee discussion: The PDCO discussed this procedure on D60. The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency’s latest decision (P/0021/2015). The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.
2.3.3.
Human coagulation factor X - Orphan - EMEA-000971-PIP01-10-M03 Bio Products Laboratory Limited; Treatment of hereditary factor X deficiency Day 60 opinion Haematology-Hemostaseology Summary of committee discussion: Based on the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted. The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency’s latest decision (P/0188/2014 of 06 August 2014). The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.
2.3.4.
Avacopan - Orphan - EMEA-002023-PIP01-16-M02 ChemoCentryx, Ltd.; Treatment of ANCA-associated vasculitis Day 60 opinion Immunology-Rheumatology-Transplantation Summary of committee discussion: Based on the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted. The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency’s latest decision (P/0268/2017 of 7 September 2017). The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.
2.3.5.
Human normal immunoglobulin for subcutaneous administration - EMEA-001853PIP01-15-M01 Grifols Therapeutics Inc; Treatment for primary immunodeficiency Day 60 opinion
Paediatric Committee (PDCO) EMA/PDCO/738440/2017
Page 15/43
Immunology-Rheumatology-Transplantation Summary of committee discussion: Based on the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted. The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency’s latest decision (P/0111/2016 of 15 April 2016). The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.
2.3.6.
Bezlotoxumab - EMEA-001645-PIP01-14-M02 Merck Sharp & Dohme (Europe), Inc.; Treatment of Clostridium difficile infection / indicated for the prevention of recurrence of Clostridium difficile infection (CDI) in paediatric patients at high risk for recurrence of CDI Day 60 opinion Infectious Diseases Summary of committee discussion: The applicant provided further clarifications, which were deemed acceptable. Otherwise the committee confirmed the outcome of the Day 30 discussion. Based on the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted. The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency’s latest decision (P/0340/2014 of 22/12/2014). The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.
2.3.7.
Ataluren - Orphan - EMEA-000115-PIP01-07-M09 PTC Therapeutics International, Limited; Treatment of dystrophinopathy ICD-10: G71.0 Muscular dystrophy [of Duchenne and Becker] / Treatment of nonsense-mutation dystrophinopathy Day 60 opinion Neurology Summary of committee discussion: The PDCO’s views expressed on day 30 were re-discussed and endorsed. The rediscussion also took into account the applicant’s clarifications and supplementary information submitted between day 30 and day 60. Based on the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted. The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP
Paediatric Committee (PDCO) EMA/PDCO/738440/2017
Page 16/43
as set in the Agency’s latest decision (P/0283/2016 of 4 November 2016). The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.
2.3.8.
Delta-9-tetrahydrocannabinol / Cannabidiol - EMEA-000181-PIP01-08-M04 GW Pharma Ltd; Spasticity / Intractable spasticity due to cerebral palsy or traumatic CNS injury Day 60 opinion Neurology Summary of committee discussion: As foreseen by the Day 30 conclusion, the PDCO adopted a negative opinion.
2.3.9.
Blinatumomab - Orphan - EMEA-000574-PIP02-12-M02 Amgen Europe B.V.; Treatment of Acute Lymphoblastic Leukaemia / Treatment of Philadelphia chromosome-negative relapsed or refractory B-precursor acute lymphoblastic leukaemia (ALL) in patients 1 month and older. Day 60 opinion Oncology Summary of committee discussion: The PDCO discussed the applicant’s request for modification for blinatumomab for the second time during its plenary on 10 November 2017. As already discussed during their day 30 discussion in October 2017, the PDCO considered that the proposed changes seemed acceptable The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency’s latest decision (P/0014/2016 of 29/01/2016). The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.
2.3.10.
Ibrutinib - Orphan - EMEA-001397-PIP03-14-M03 Janssen-Cilag International N.V.; Treatment of mature B-cell neoplasms / Treatment of children from 1 year to less than 18 years of age with newly-diagnosed and relapsed/refractory mature B-cell lymphoma, that is, diffuse large B-cell lymphoma or Burkitt and Burkitt-like lymphoma. Day 60 opinion Oncology Summary of committee discussion: The PDCO re-discussed the proposed modification also taking into account the clarifications provided by the applicant after the D30 discussion. All the issues were considered solved.
Paediatric Committee (PDCO) EMA/PDCO/738440/2017
Page 17/43
Based on the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted. The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency’s latest decision (P/0100/2017 of 11 April 2017). The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.
2.3.11.
Inotuzumb ozogamicin - Orphan - EMEA-001429-PIP01-13-M02 Pfizer Ltd; Treatment of Acute Lymphoblastic Leukaemia / For the treatment of relapsed or refractory B cell precursor Acute Lymphoblastic Leukaemia Day 60 opinion Oncology / Haematology-Hemostaseology Summary of committee discussion: The PDCO accepted the modifications proposed by the applicant.
2.3.12.
Human Thrombin / Human Fibrinogen - EMEA-001149-PIP01-11-M04 Omrix Biopharmaceuticals N.V.; Treatment of cerebrospinal fluid leakage resulting from a surgical procedure, Treatment of haemorrhage resulting from a surgical procedure / indicated for suture line sealing in dura mater closure., indicated for supportive treatment in surgery where standard surgical techniques are insufficient, for improvement of haemostasis., indicated for supportive treatment in surgery where standard surgical techniques are insufficient, for improvement of haemostasis. Day 60 opinion Other Summary of committee discussion: Based on the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted. The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency’s latest decision (P/0067/2016 of 18 March 2016). The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.
2.3.13.
Lanadelumab - Orphan - EMEA-001864-PIP01-15-M01 Shire Pharmaceuticals Ireland Limited; Treatment of hereditary angioedema Day 60 opinion Other Summary of committee discussion:
Paediatric Committee (PDCO) EMA/PDCO/738440/2017
Page 18/43
The PDCO discussed the applicant’s request for modification for Lanadelumab and the additional clarifications provided. All outstanding issues have been addressed satisfactorily. The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency’s latest decision (P/0273/2016 of 05/10/2016). The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.
2.3.14.
Sildenafil - Orphan - EMEA-000671-PIP01-09-M09 Pfizer Limited; Treatment of Pulmonary Arterial Hypertension (PAH) Day 60 opinion Other Summary of committee discussion: Based on the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes to the timelines could be accepted. The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency’s latest decision (P/0092/2015 of 8 May 2015). The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.
2.3.15.
Aluminium hydroxide adsorbed, depigmented glutaraldehyde polymerised, allergen extract of Phleum pratense, Dactylis glomerata, Festuca elatior, Lolium perenne and Poa pratensis pollen (Grasses-Mix) (1/5) each - EMEA-000794PIP01-09-M01 LETI Pharma GmbH; J 30.1 Allergic rhinitis due to pollen, J 30.2 Other seasonal allergic rhinitis,, H10.1 Acute allergic conjunctivitis, J30.3 Other allergic rhinitis, J30.4 Allergic rhinitis, unspecified / Treatment of patients with allergic rhinitis with or without intermittent allergic asthma due to sensitisation against grass pollens (Gramineas family), Treatment of patients with allergic rhinoconjunctivitis with or without intermittent allergic asthma due to sensitisation against grass pollens (Gramineas family) Day 60 opinion Pneumology - Allergology Summary of committee discussion: The PDCO’s views expressed on day 30 were re-discussed and endorsed. Based on the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted. The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency’s latest decision of 26 November 2010. The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.
Paediatric Committee (PDCO) EMA/PDCO/738440/2017
Page 19/43
2.3.16.
Aluminium hydroxide adsorbed, depigmented glutaraldehyde polymerised, allergen extract of Phleum pratense, Dactylis glomerata, Festuca elatior, Lolium perenne and Poa pratensis pollen (Grasses-Mix) and Secale cereale (Cultivated Rye) pollen (50/50) - EMEA-000792-PIP01-09-M01 LETI Pharma GmbH; J 30.1 Allergic rhinitis due to pollen, J 30.2 Other seasonal allergic rhinitis,, H10.1 Acute allergic conjunctivitis, J30.3 Other allergic rhinitis, J30.4 Allergic rhinitis, unspecified / Treatment of patients with allergic rhinitis with or without intermittent allergic asthma due to sensitisation against grass pollens (Gramineas family), Treatment of patients with allergic rhinoconjunctivitis with or without intermittent allergic asthma due to sensitisation against grass pollens (Gramineas family) Day 60 opinion Pneumology - Allergology Summary of committee discussion: The PDCO’s views expressed on day 30 were re-discussed and endorsed. Based on the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted. The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency’s latest decision of 26 November 2010. The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.
2.3.17.
Aluminium hydroxide adsorbed, depigmented glutaraldehyde polymerised, allergic extract of Phleum pratense pollen - EMEA-000795-PIP01-09-M01 LETI Pharma GmbH; J 30.1 Allergic rhinitis due to pollen, J 30.2 Other seasonal allergic rhinitis,, H10.1 Acute allergic conjunctivitis, J30.3 Other allergic rhinitis, J30.4 Allergic rhinitis, unspecified / Treatment of patients with allergic rhinitis with or without intermittent allergic asthma due to sensitisation against grass pollens (Gramineas family), Treatment of patients with allergic rhinoconjunctivitis with or without intermittent allergic asthma due to sensitisation against grass pollens (Gramineas family) Day 60 opinion Pneumology - Allergology Summary of committee discussion: The PDCO’s views expressed on day 30 were re-discussed and endorsed. Based on the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted. The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency’s latest decision of 26 November 2010. The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.
Paediatric Committee (PDCO) EMA/PDCO/738440/2017
Page 20/43
2.4.
Opinions on Re-examinations
2.4.1.
Crisaborole - EMEA-002065-PIP01-16 Pfizer Ltd; Mild to moderate atopic dermatitis Day 30 opinion Dermatology Summary of committee discussion: The Opinion was adopted via a written procedure on 31 October 2017. In conclusion, the PDCO maintains its opinion.
2.5.
Finalisation and adoption of opinions
3.
Discussion of applications
Disclosure of some information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.
3.1.
Discussions on Products D90-D60-D30
3.1.1.
Chloroprocaine Hydrochloride - EMEA-000639-PIP03-16 Peripheral nerve block (local anesthesia by perineural injection) Day 90 discussion Anaesthesiology
3.1.2.
Lucerastat - Orphan - EMEA-002095-PIP01-16 Idorsia Pharmaceuticals Deutschland GmbH; Treatment of Fabry disease Day 90 discussion Endocrinology-Gynaecology-Fertility-Metabolism
3.1.3.
EMEA-002109-PIP01-16 K75.8 Other specified inflammatory liver diseases (non-alcoholic steatohepatitis [NASH]) / Treatment of Non-Alcoholic Steatohepatitis (NASH) with mild to severe fibrosis (F1-F4) in paediatric subjects, 8 to < 18 years of age Day 90 discussion Gastroenterology-Hepatology
Paediatric Committee (PDCO) EMA/PDCO/738440/2017
Page 21/43
3.1.4.
Maralixibat Chloride - Orphan - EMEA-001475-PIP03-17 Shire Pharmaceuticals Ireland Limited; Treatment of Progressive Familial Intrahepatic Cholestasis Day 90 discussion Gastroenterology-Hepatology
3.1.5.
Glutamine (Levoglutamide) - Orphan - EMEA-001996-PIP02-16 Emmaus Medical Europe Ltd.; Sickle cell disease / Glutamine (Levoglutamide) is indicated for the prevention of sickle cell crises in adults and children older than 5 years suffering from Sickle Cell Disease. Day 90 discussion Haematology-Hemostaseology
3.1.6.
Upadacitinib - EMEA-001741-PIP02-16 Treatment of Uclerative Colitis Day 90 discussion Immunology-Rheumatology-Transplantation
3.1.7.
Obiltoxaximab - EMEA-002144-PIP01-17 Treatment of bacillary infection, Prevention of bacillary infection / Treatment of inhalation anthrax following exposure to Bacillus anthracis in combination with appropriate antibacterial drugs, Post-exposure prophylaxis of inhalation anthrax when alternative therapies are not available or are not appropriate Day 90 discussion Infectious Diseases
3.1.8.
Gilteritinib (as fumarate) - EMEA-002064-PIP01-16 Treatment of acute myeloid leukemia / Treatment of FLT3/ITD positive acute myeloid leukemia Day 90 discussion Oncology / Haematology-Hemostaseology
3.1.9.
Recombinant Clostridium difficile Toxoid B / Recombinant Clostridium difficile Toxoid A - EMEA-002112-PIP01-16 Prevention of Clostridium difficile infection (CDI) / Active immunization for the prevention of primary Clostridium difficile infection in children and adolescents 2 to 18 years of age
Paediatric Committee (PDCO) EMA/PDCO/738440/2017
Page 22/43
Day 90 discussion Vaccines
3.1.10.
EMEA-001527-PIP02-17 Treatment of obesity Day 60 discussion Endocrinology-Gynaecology-Fertility-Metabolism
3.1.11.
Itacitinib - EMEA-002178-PIP01-17 Treatment of acute Graft versus Host Disease (D89.810, ICD-10-CM) / Treatment of steroid naïve paediatric population with acute graft versus host disease after allogeneic hematopoietic stem cell transplantation Day 60 discussion Immunology-Rheumatology-Transplantation
3.1.12.
Fremanezumab - EMEA-001877-PIP03-17 Prevention of cluster headache Day 60 discussion Neurology
3.1.13.
Setmelanotide - Orphan - EMEA-002209-PIP01-17 Rhythm Pharmaceuticals, Inc; Treatment of appetite and general nutrition disorders / Treatment of obesity and/or hyperphagia associated with genetic defects upstream of the MC4 receptor in the leptin-melanocortin pathway Day 60 discussion Nutrition
3.1.14.
Afatinib - EMEA-001596-PIP02-17 Treatment of oropharyngeal, laryngeal or nasal epithelial carcinoma, Treatment of paediatric patients with tumours with known ErbB deregulations irrespective of tumour histology, Treatment of lung carcinoma, Treatment of urether and bladder carcinoma / Treatment of paediatric patients aged between ≥ 1 year and ≤ 18 years with recurrent or refractory tumours with known ErbB deregulation and irrespective of tumour histology. Day 60 discussion Oncology
Paediatric Committee (PDCO) EMA/PDCO/738440/2017
Page 23/43
3.1.15.
Fosnetupitant / palonosetron - EMEA-001198-PIP03-17 Prevention of Chemotherapy-Induced Nausea and Vomiting Day 60 discussion Other
3.1.16.
EMEA-002160-PIP01-17 Prevention of human immunodeficiency virus (HIV-1) infection / Prevention of HIV-1 infection in children from 9 to less than 18 years of age Day 60 discussion Vaccines / Infectious Diseases
3.1.17.
Clade C gp140 - EMEA-002221-PIP01-17 Prevention of human immunodeficiency virus (HIV-1) infection / Prevention of HIV-1 infection in children from 9 to less than 18 years of age Day 60 discussion Vaccines / Infectious Diseases
3.1.18.
Mosaic gp140 / Clade C gp140 - EMEA-002161-PIP01-17 Prevention of human immunodeficiency virus (HIV-1) infection / Prevention of HIV-1 infection in children from 9 to less than 18 years of age Day 60 discussion Vaccines / Infectious Diseases
3.1.19.
Rosuvastatin calcium / Acetylsalicylic acid - EMEA-002239-PIP01-17 Prevention of cardiovascular events Day 30 discussion Cardiovascular Diseases
3.1.20.
Baricitinib - EMEA-001220-PIP03-16 Treatment of atopic dermatitis / Treatment of patients with moderate to severe atopic dermatitis Day 30 discussion Dermatology
Paediatric Committee (PDCO) EMA/PDCO/738440/2017
Page 24/43
3.1.21.
Fluorocholine (18F) - EMEA-002129-PIP02-17 Visualisation of choline metabolism in malignant neoplasms Day 30 discussion Diagnostic
3.1.22.
Bis-choline tetrathiomolybdate - Orphan - EMEA-002232-PIP01-17 Wilson Therapeutics AB; Treatment of Wilson disease Day 30 discussion Endocrinology-Gynaecology-Fertility-Metabolism
3.1.23.
Ethinyl estradiol / Dienogest - EMEA-002229-PIP01-17 Contraception / Oral contraception Day 30 discussion Endocrinology-Gynaecology-Fertility-Metabolism
3.1.24.
Semaglutide - EMEA-001441-PIP03-17 Treatment of obesity Day 30 discussion Endocrinology-Gynaecology-Fertility-Metabolism
3.1.25.
Orphan - EMEA-002233-PIP01-17 Zealand Pharma A/S; Treatment of hypoglycaemia Day 30 discussion Endocrinology-Gynaecology-Fertility-Metabolism
3.1.26.
Amiselimod - EMEA-002227-PIP01-17 Ulcerative colitis / Treatment of moderately to severely active UC in children and adolescents who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy, a TNF-alpha antagonist, or an integrin inhibitor. Day 30 discussion Gastroenterology-Hepatology
3.1.27.
Ustekinumab - EMEA-000311-PIP05-17 Treatment of Ulcerative Colitis
Paediatric Committee (PDCO) EMA/PDCO/738440/2017
Page 25/43
Day 30 discussion Gastroenterology-Hepatology
3.1.28.
(6aR,10aR)-1-Hydroxy-6,6-dimethyl-3-(2-methyl-2-octanyl)-6a,7,10,10atetrahydro-6H-benzo[c]chromene-9-carboxylic acid - Orphan - EMEA-002069PIP02-17 Corbus Pharmaceuticals Holdings Inc; Treatment of systemic sclerosis Day 30 discussion Immunology-Rheumatology-Transplantation
3.1.29.
Riociguat - Orphan - EMEA-000718-PIP03-17 Bayer AG; Treatment of Systemic Sclerosis / Treatment of Diffuse Cutaneous Systemic Sclerosis (dcSSc) Day 30 discussion Immunology-Rheumatology-Transplantation
3.1.30.
The whole range of unmanipulated autologous mononuclear cells derived from human umbilical cord blood (Hau-UCB-mnc) - Orphan - EMEA-001799-PIP02-17 BrainRepair UG (haftungsbeschränkt); Periventriculaleukomalacia (PVL) ICD-10-CM P91.2 Day 30 discussion Neonatology - Paediatric Intensive Care
3.1.31.
Vatiquinone - Orphan - EMEA-002235-PIP01-17 Edison Orphan Pharma BV; RARS2 syndrome (ICD10 code G31.9) Day 30 discussion Neurology
3.1.32.
Tucatinib - EMEA-002242-PIP01-17 Treatment of breast malignant neoplasms Day 30 discussion Oncology
3.1.33.
Recombinant human epidermal growth factor - EMEA-002258-PIP01-17 Diabetic foot ulcer
Paediatric Committee (PDCO) EMA/PDCO/738440/2017
Page 26/43
Day 30 discussion Other / Endocrinology-Gynaecology-Fertility-Metabolism
3.1.34.
Human donor hematopoietic stem and progenitor cells (HSPC) that have been treated ex vivo with Tat-MYC fusion protein - Orphan - EMEA-002185-PIP02-17 Taiga Biotechnologies, Inc.; Severe Combined Immunodeficiency Day 30 discussion Other / Immunology-Rheumatology-Transplantation
3.1.35.
Purified Rabies virus - EMEA-002234-PIP01-17 Prevention of rabies disease, treatment of exposure to rabies virus Day 30 discussion Vaccines
3.2.
Discussions on Compliance Check The following compliance checks have been put up for discussion and the members of the PDCO have been invited to comment on issues of possible non-compliance
3.2.1.
Clostridium Botulinum neurotoxin type A (150 kD) - EMEA-C-001039-PIP01-10M02 Merz Pharmaceuticals GmbH; Treatment of muscle spasticity Day 30 discussion Neurology
3.2.2.
Clostridium Botulinum neurotoxin type A (150 kD) - EMEA-C1-001039-PIP02-12M02 Merz Pharmaceuticals GmbH; Treatment of sialorrhea Day 30 discussion Neurology
3.2.3.
Japanese-encephalitis virus, inactivated - EMEA-C-000559-PIP01-09-M04 Valneva Austria GmbH; Prevention of Japanese encephalitis Day 30 discussion Vaccines
Paediatric Committee (PDCO) EMA/PDCO/738440/2017
Page 27/43
3.3.
Discussions on Modification of an Agreed Paediatric Investigation Plan
3.3.1.
Regadenoson - EMEA-000410-PIP01-08-M02 Rapidscan Pharma Solutions EU Limited; Myocardial perfusion disturbances / Diagnostic evaluation of myocardial perfusion disturbances Day 30 discussion Cardiovascular Diseases
3.3.2.
Gadolinium,[α3,α6,α9-tris[3-[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-3oxopropyl]-3,6,9,15-tetraazabicyclo[9.3.1]pentadeca-1(15),11,13-triene-3,6,9triacetato(3-)-κN3,κN6,κN9,κN15,κO3,κO6,κO9] - EMEA-001949-PIP01-16-M01 GUERBET; Detection and visualization of areas with disruption of the blood brain barrier and/or abnormal vascularity for the central nervous system (CNS), or of any type of diseases from different body regions (soft tissues, bone and internal body structures/organs) for diagnostic purposes. Day 30 discussion Diagnostic
3.3.3.
Empagliflozin - EMEA-000828-PIP01-09-M06 Boehringer Ingelheim International GmbH; Treatment of type 2 diabetes mellitus Day 30 discussion Endocrinology-Gynaecology-Fertility-Metabolism
3.3.4.
Linagliptin (as base) - EMEA-000498-PIP01-08-M07 Boehringer Ingelheim International GmbH; Type 2 Diabetes Mellitus Day 30 discussion Endocrinology-Gynaecology-Fertility-Metabolism
3.3.5.
Sitagliptin phosphate - EMEA-000470-PIP01-08-M10 Merck Sharp and Dohme (Europe), Inc.; Treatment of type 2 diabetes mellitus Day 30 discussion Endocrinology-Gynaecology-Fertility-Metabolism
3.3.6.
Baricitinib - EMEA-001220-PIP01-11-M02 Eli Lilly and Company Limited; Treatment of chronic idiopathic arthritis (including
Paediatric Committee (PDCO) EMA/PDCO/738440/2017
Page 28/43
rheumatoid arthritis, ankylosing spondylarthritis, psoriatic arthritis and juvenile idiopathic arthritis) / Treatment of juvenile idiopathic arthritis, Treatment of JIA-associated uveitis Day 30 discussion Immunology-Rheumatology-Transplantation
3.3.7.
Human normal immunoglobulin - EMEA-001797-PIP01-15-M01 Octapharma Pharmazeutika Produktionsges.m.b.H; Primary Immunodeficiency Diseases Day 30 discussion Immunology-Rheumatology-Transplantation
3.3.8.
Ixekizumab - EMEA-001050-PIP01-10-M03 Eli Lilly & Company Limited; Plaque psoriasis, Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylarthritis and juvenile idiopathic arthritis) / Children with juvenile idiopathic arthritis subtypes of enthesitisrelated arthritis (including JoAS) and juvenile psoriatic arthritis., Treatment of severe chronic plaque psoriasis in paediatric patients from the age of 6 years who are not adequately controlled by topical therapies. Day 30 discussion Immunology-Rheumatology-Transplantation
3.3.9.
Tofacitinib - EMEA-000576-PIP01-09-M08 Pfizer Limited; Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and juvenile idiopathic arthritis) / Juvenile Idiopathic arthritis Day 30 discussion Immunology-Rheumatology-Transplantation
3.3.10.
Ustekinumab - EMEA-000311-PIP03-11-M03 Janssen-Cilag International NV; Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, spondyloarthritis, PsA and juvenile idiopathic arthritis [JIA]) Day 30 discussion Immunology-Rheumatology-Transplantation
3.3.11.
Ceftaroline fosamil - EMEA-000769-PIP01-09-M07 Pfizer Limited; Treatment of cSSTI (complicated skin and soft tissue infections) / Treatment of CAP (community-aquired pneumonia)
Paediatric Committee (PDCO) EMA/PDCO/738440/2017
Page 29/43
Day 30 discussion Infectious Diseases
3.3.12.
Cobicistat / atazanavir sulphate - EMEA-001465-PIP01-13-M02 Bristol-Myers Squibb Pharma EEIG; Treatment of HIV-1 infection / indicated in combination with other ARV medicinal products for the treatment of HIV-1 infected adults and children from 3 years of age without known mutations associated with resistance to atazanavir. Day 30 discussion Infectious Diseases
3.3.13.
Oseltamivir phosphate - EMEA-000365-PIP01-08-M09 Roche Registration Limited; Treatment and prevention of influenza / Treatment and prevention of influenza in healthy and immunocompromised patients from 0 to less than 18 years of age Day 30 discussion Infectious Diseases
3.3.14.
Posaconazole - EMEA-000468-PIP02-12-M04 Merck Sharp & Dohme (Europe), Inc.; Prevention of invasive fungal infections / For treatment of invasive fungal infections in the following paediatric patients: -Invasive aspergillosis in patients with disease that is refractroy to amphotericin B or itraconazole or in patients who are intolerant of these medicinal products; Treatment of invasive aspergillosis, -Patients receiving remission-induction chemotherapy for acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections; - Hematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections. Day 30 discussion Infectious Diseases
3.3.15.
Tedizolid phosphate - EMEA-001379-PIP01-12-M03 Merck Sharp & Dohme (Europe) Inc.; Treatment of acute bacterial skin and skin structure infections Day 30 discussion Infectious Diseases
Paediatric Committee (PDCO) EMA/PDCO/738440/2017
Page 30/43
3.3.16.
Tenofovir alafenamide - EMEA-001584-PIP01-13-M03 Gilead Sciences International Ltd.; Treatment of chronic hepatitis B / indicated for the treatment of chronic hepatitis B infection in paediatric patients aged 2 years and above. Day 30 discussion Infectious Diseases
3.3.17.
Lacosamide - EMEA-000402-PIP02-11-M05 UCB Pharma S.A.; Treatment of Epilepsy - Partial-onset seizures [G40.0 - G40.1 - G40.2] Day 30 discussion Neurology
3.3.18.
Midostaurin - Orphan - EMEA-000780-PIP01-09-M04 Novartis Europharm Ltd; C92.0 Acute myeloid leukaemia, C94.3 Mast cell leukaemia, C96.2 Malignant mastocytosis / Treatment of paediatric patients with FLT3 mutated AML, newly diagnosed Day 30 discussion Oncology
3.3.19.
Pembrolizumab - EMEA-001474-PIP02-16-M01 Merck Sharp & Dohme (Europe), Inc.; Treatment of all conditions included in the category of malignant neoplasms (except nervous system, haematopoietic and lymphoid tissue)., Treatment of Hodgkin Lymphoma / Treatment of advanced, untreated or previously treated, malignant melanoma in children from 12 year old to less than 18 years of age. Treatment as monotherapy of a PD-L1 positive paediatric malignant solid tumor in children from 6 months to less than 18 years of age., •Treatment of classical Hodgkin lymphoma with incomplete early response to front-linechemotherapy in children from 3 years to less than 18 years of age •Treatment of relapsed or refractory classical Hodgkin lymphoma in children from 5 years to lessthan 18 years of age Day 30 discussion Oncology
3.3.20.
Burosumab; Human recombinant IgG1 monoclonal antibody to fibroblast growth factor 23 (FGF23); - Orphan - EMEA-001659-PIP01-15-M03 Ultragenyx Pharmaceutical Inc.; X-linked Hypophosphatemia Day 30 discussion Other
Paediatric Committee (PDCO) EMA/PDCO/738440/2017
Page 31/43
3.3.21.
Conestat alfa - EMEA-000367-PIP01-08-M07 Pharming Group N.V.; D84.1 Defects in the complement system C1 esterase inhibitor (C1-INH) deficiency / Treatment of acute attacks of angioedema associated with hereditary C1 esterase inhibitor deficiency Day 30 discussion Other
3.3.22.
Ivacaftor / lumacaftor - EMEA-001582-PIP01-13-M07 Vertex Pharmaceuticals (Europe) Limited; cystic fibrosis / Treatment of cystic fibrosis Day 30 discussion Other
3.3.23.
Matrix applied characterised autologous cultured chondrocytes - EMEA-000979PIP01-10-M02 Vericel Denmark ApS; repair of symptomatic, full-thickness cartilage defects of the knee Day 30 discussion Other
3.3.24.
Birch pollen extract (Betula verrucosa) - EMEA-001879-PIP01-15-M01 ALK Abelló A/S; J30.1 Allergic rhinitis due to pollen / Treatment of tree pollen allergic rhinitis and/or conjunctivitis Day 30 discussion Pneumology - Allergology
3.3.25.
Reslizumab - EMEA-001202-PIP02-13-M02 Teva Pharmaceuticals Europe; Treatment of asthma / indicated as add‑ on treatment in adult patients with severe eosinophilic asthma Day 30 discussion Pneumology - Allergology
3.3.26.
N-[(1,3-dicyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5pyrimidinyl)carbonyl]glycine - EMEA-001452-PIP01-13-M01 GlaxoSmithKline R & D; Treatment of anaemia associated with chronic renal disease Day 30 discussion Uro-nephrology / Haematology-Hemostaseology
Paediatric Committee (PDCO) EMA/PDCO/738440/2017
Page 32/43
3.3.27.
Outer Membrane Vescicles (OMV) from Neisseria Meningitidis serogroup B strain NZ98/254 measured as amount of total protein containing the PorA P1.4 / Recombinant Neisseria Meningitidis serogroup B fHbp fusion protein / Recombinant Neisseria Meningitidis serogroup B NadA protein / Recombinant Neisseria Meningitidis serogroup B NHBA fusion protein - EMEA-000139-PIP0107-M02 GSK Vaccines S.r.l.; Prevention of meningitis Day 30 discussion Vaccines
4.
Nominations
Disclosure of information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.
4.1.
List of letters of intent received for submission of applications with start of procedure 23 January 2018 for Nomination of Rapporteur and Peer reviewer Summary of committee discussion: The PDCO approved the lists of Rapporteurs and Peer Reviewers.
4.2.
Nomination of Rapporteur for requests of confirmation on the applicability of the EMA decision on class waiver. Summary of committee discussion: The PDCO approved the lists of Rapporteurs and Peer Reviewers.
4.3.
Nominations for other activities Summary of committee discussion: None
5.
Scientific Advice Working Party (SAWP) and Paediatric Committee (PDCO) Interaction
Disclosure of information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.
6.
Discussion on the applicability of class waivers
Disclosure of some information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.
Paediatric Committee (PDCO) EMA/PDCO/738440/2017
Page 33/43
6.1.
Discussions on the applicability of class waiver for products None
7.
Discussion on the inclusion of an indication within a condition in an agreed PIP/waiver
7.1.
Discussion on the possibility to include an indication within a condition in an agreed PIP/waiver
7.1.1.
Rivaroxaban - EMEA-000430-PIP01-08-M10 Bayer AG; Prevention of thromboembolic events/ Prevention of stroke, myocardial infarction and cardiovascular death, and for the prevention of acute limb ischemia and mortality in adult patients with Coronary Artery Disease or Peripheral Artery Disease Summary of committee discussion: The PDCO confirmed that the proposed indication “prevention of stroke, myocardial infarction and cardiovascular death, and for the prevention of acute limb ischemia and mortality in adult patients with Coronary Artery Disease or Peripheral Artery Disease”, is considered to be covered by the condition “prevention of thromboembolic events”.
8.
Annual reports on deferrals Note: The annual reports on deferrals to be noted by the members of the PDCO are flagged in the Annex B.
9.
Organisational, regulatory and methodological matters
9.1.
Mandate and organisation of the PDCO
9.1.1.
User manual on CxMP/EMA external representation Summary of committee discussion: The user manual describes the process for allowing a scientific committee (CxMP), working party (WP) or scientific advisory group (SAG) chair, member, alternate or expert to participate in an external meeting or conference representing the CxMP or the European Medicines Agency (EMA or Agency) in an official capacity, where the participation is fully or partially reimbursed by the Agency or by the organiser of the meeting or conference. The PDCO noted the user manual.
9.2. 9.2.1.
Coordination with EMA Scientific Committees or CMDh-v Committee for Medicinal Products for Human Use (CHMP) Summary of committee discussion: The list of procedures with paediatric indications to be evaluated by the CHMP, starting in
Paediatric Committee (PDCO) EMA/PDCO/738440/2017
Page 34/43
October 2017 was presented to the PDCO members. The members were also informed about 2 medicinal products, Cubicin and Pegasys for which the CHMP adopted a positive opinion recommending a paediatric indication during their meeting in October 2017.
9.2.2.
CHMP Oncology Working Party Workshop on: Histology – independent indications in Oncology PDCO member: Koenraad Norga Summary of committee discussion: The PDCO was informed about the Workshop.
9.2.3.
CHMP-PDCO common session Summary of committee discussion: The CHMP-PDCO common session took place.
9.2.4.
Questions from PRAC to PDCO following a MS request for PRAC Advice
Summary of committee discussion: The questions of the PRAC have been presented to the PDCO; volunteers to work on the draft response have been identified.
9.3.
Coordination with EMA Working Parties/Working Groups/Drafting Groups
9.3.1.
Non-clinical Working Group: D30 Products identified PDCO member: Karen van Malderen Summary of committee discussion: The chair of the Non-clinical Working Group identified the products which will require Non-clinical Working Group evaluation and discussion.
9.3.2.
Non-clinical Working Group: Call for additional members Summary of committee discussion: The call for additional members to the Non-clinical Working Group has been announced to the PDCO.
9.3.3.
Formulation Working Group PDCO member: Brian Aylward Summary of committee discussion:
Paediatric Committee (PDCO) EMA/PDCO/738440/2017
Page 35/43
The chair of the Formulation Working Group identified the products which will require Formulation Working Group evaluation and discussion.
9.3.4.
Formulation Working Group: PDCO FWG participants 2018 PDCO member: Brian Aylward Summary of committee discussion: The PDCO adopted the list of PDCO FWG experts for the year 2018.
9.3.5.
Guideline on the development of new medicinal products for the treatment of Crohn’s Disease and ulcerative colitis – POSTPONED TO DECEMBER PDCO member: Peter Szitanyi The topic was postponed to December PDCO.
9.3.6.
Guideline on the clinical evaluation of vaccines Revised draft for comments by 14 November 2017 Summary of committee discussion: The Committee was introduced to the scope of the revised draft guideline and invited to comment.
9.3.7.
Minutes of the PCWP/HCPWP joint meeting held on 20 September 2017 The document was tabled for information.
9.3.8.
FDA Public Workshop- Advancing the Development of Pediatric Therapeutics (ADEPT) Application of "Big Data" to Pediatric Safety Studies - Report from the meeting Summary of committee discussion: Key messages were presented arising from a recent workshop organised by the FDA entitled “Application of “Big Data” to Paediatric Safety Studies” under the umbrella of ADEPT (Advancing the Development of Paediatric Therapeutics). The workshop focussed predominantly on big data in the context of real world data (RWD).
9.4.
Cooperation within the EU regulatory network
9.4.1.
European Network of Paediatric Research (Enpr) - European Medicines Agency (EMA) Summary of committee discussion: the coordinator of the German Neonatal Network (GNN) presented the structure, aims and current projects of the network to the PDCO. GNN, which encompasses more than 60 neonatal intensive care units in Germany and is funded by the German Federal Ministry
Paediatric Committee (PDCO) EMA/PDCO/738440/2017
Page 36/43
of Education and Research (BMBF), is a basic research network. The network started patient enrolment in 2009 and aims to enrol more than 20,000 preterm infants with a birth weight below 1500 grams over 12 years (i.e. by 2021) into an academic prospective cohort study investigating the long-term effects of genetic, clinical and social risk factors, and the influence of centre specific treatment strategies on short and long-term development of preterm neonates. The development of these infants will be followed up during a time period of six years. The network promotes urgently needed randomised clinical trials in very low birth weight infants. The network already has and is willing to offer advice to companies on neonatal trial issues if approached e.g. in preparation of a PIP submission.
9.4.2.
European Commission 10 Year report of the Paediatric regulation Summary of committee discussion: EC representative gave a presentation on ‘10 Year report of the Paediatric regulation’.
9.5.
Cooperation with International Regulators None
9.6.
Contacts of the PDCO with external parties and interaction with the Interested Parties to the Committee None
9.7.
PDCO work plan
9.7.1.
Draft PDCO Work plan 2018 Summary of committee discussion: The Committee discussed the draft PDCO Work plan for 2018.
9.8.
Planning and reporting
9.8.1.
Report on the PDCO Strategic Review & Learning meeting in Tallinn, 4-6 October 2017 PDCO member: Irja Lutsar Summary of committee discussion: The Committee was provided with feedback from the PDCO Strategic Review & Learning meeting held in Tallinn on 4-6 October 2017.
Paediatric Committee (PDCO) EMA/PDCO/738440/2017
Page 37/43
10.
Any other business
10.1.
AOB topic
11.
Breakout sessions
11.1.1.
Paediatric oncology Summary of committee discussion: The group discussed about the forthcoming ‘paediatric strategy forum on medicine development for mature B cell malignancies in children’ and on academic community’s view on frontline studies in oncology PIPs.
11.1.2.
Neonatology Summary of committee discussion: The breakout session has been cancelled.
11.1.3.
Inventory Summary of committee discussion: The Paediatric Inventory Group convened to progress on the methodology to be used for the identification of unmet needs through the paediatric investigation plans assessed by the PDCO.
The Chair thanked all participants and closed the meeting.
Paediatric Committee (PDCO) EMA/PDCO/738440/2017
Page 38/43
12.
List of participants
List of participants including any restrictions with respect to involvement of members/alternates/ experts following evaluation of declared interests for the 7 – 10 November 2017 meeting. Name
Role
Member
Outcome
Topics on agenda for which
State or
restriction
restrictions apply
affiliation
following evaluation of e-DoI
Dirk Mentzer
Chair
Germany
No interests declared
Karl-Heinz
Member
Austria
Huemer Johanna
declared Alternate
Austria
Wernsperger Koenraad Norga
No interests
No interests declared
Member
Belgium
(Vice-Chair)
When chairing
EMEA-000139-PIP01-07-M02
the meeting:
EMEA-C-000069-PIP02-10-M08
To be replaced
EMEA-001452-PIP01-13-M01
for discussions, final deliberations and voting When not chairing the meeting: No participation in final deliberations and voting Karen Van
Alternate
Belgium
Malderen Dimitar
No interests declared
Member
Bulgaria
No restrictions applicable to
Roussinov
this meeting Adriana Andrić
Member
Croatia
No interests declared
Suzana Mimica
Alternate
Croatia
Matanovic Georgios Savva
No interests declared
Member
Cyprus
No interests declared
Paediatric Committee (PDCO) EMA/PDCO/738440/2017
Page 39/43
Name
Role
Member
Outcome
Topics on agenda for which
State or
restriction
restrictions apply
affiliation
following evaluation of e-DoI
Jaroslav Sterba
Member
Czech Republic
No interests declared
Peter Szitanyi
Alternate
Czech Republic
No interests declared
Marianne
Member
Denmark
Orholm Kirstine Moll
declared Alternate
Denmark
Harboe Irja Lutsar
No interests
No interests declared
Member
Estonia
No interests declared
Ann Marie
Member
Finland
Kaukonen Sylvie Benchetrit
No interests declared
Member
France
No interests declared
Dominique Ploin
Alternate
France
No interests declared
Sabine Scherer
Member
Germany
No interests declared
Immanuel Barth
Alternate
Germany
No interests declared
Eleni Katsomiti
Member
Greece
No interests declared
Ágnes Gyurasics
Member
Hungary
(CHMP
No interests declared
member) Brian Aylward
Member
Ireland
No interests declared
Sara Galluzzo
Member
Italy
No interests declared
Alessandro
Alternate
Italy
Jenkner Dina Apele-
declared Member
Latvia
Freimane Sigita Burokiene
No interests
No interests declared
Member
Paediatric Committee (PDCO) EMA/PDCO/738440/2017
Lithuania
No interests
Page 40/43
Name
Role
Member
Outcome
Topics on agenda for which
State or
restriction
restrictions apply
affiliation
following evaluation of e-DoI declared
Carola de
Member
Beaufort
(CHMP
Luxembourg
No interests declared
alternate) Maaike van
Member
Netherlands
Dartel Siri Wang
No interests declared
Member
Norway
No interests declared
Marek Migdal
Member
Poland
No interests declared
Helena Fonseca
Member
Portugal
No interests declared
Hugo Tavares
Alternate
Portugal
No interests declared
Dana Gabriela
Member
Marin
(CHMP
Romania
No interests declared
alternate) Peter Sisovsky
Member
Slovakia
No interests declared
Stefan Grosek
Member
Slovenia
No interests declared
Fernando de
Member
Spain
Andrés Trelles Maria Jesús
No interests declared
Alternate
Spain
Fernández
No interests declared
Cortizo Eva Agurell
Alternate
Sweden
No restrictions applicable to this meeting
Angeliki
Member
Siapkara Martina Riegl
Fernando
Alternate
Member
United
No interests
Kingdom
declared
United
No interests
Kingdom
declared
Healthcare
No interests
Professionals'
Paediatric Committee (PDCO) EMA/PDCO/738440/2017
Page 41/43
Name
Role
Member
Outcome
Topics on agenda for which
State or
restriction
restrictions apply
affiliation
following evaluation of e-DoI
Cabanas Riccardo Riccardi
Johannes
Alternate
Member
Taminiau
Representative
declared
Healthcare
No restrictions
Professionals'
applicable to
Representative
this meeting
Healthcare
No interests
Professionals'
declared
Representative Dimitrios
Member
Athanasiou
Patients’
No interests
Organisation
declared
Representative Shiva Ramroop
Expert - in
United
No restrictions
person*
Kidgdom
applicable to this meeting
Wolfgang Göpel
Expert - in
Germany
No restrictions applicable to
person*
this meeting Sara Homer
Expert - in
United
No interests
person*
Kingdom
declared
Representative from the European Commission participated in the meeting Meeting run with support from relevant EMA staff * Experts were only evaluated against the product(s) they have been invited to talk about.
Paediatric Committee (PDCO) EMA/PDCO/738440/2017
Page 42/43
13.
Explanatory notes
The Notes give a brief explanation of relevant agenda items and should be read in conjunction with the agenda. Paediatric investigation plan (PIP) (section 2.1 Opinion on PIPs and section 3.1 Discussions on PIPs) A paediatric investigation plan (PIP) is a development plan aimed at ensuring that the necessary data are obtained through studies in children, when it is safe to do so, to support the authorisation of a medicine for children. Pharmaceutical companies submit proposals for PIPs to the European Medicines Agency's Paediatric Committee (PDCO). This Committee is responsible for agreeing or refusing the plan. Compliance checks (section 2.2 Opinions on Compliance check, section 3.2 Discussions on Compliance check) A compliance check may be necessary before any application for marketing authorisation (even for an adult indication) can be considered valid, if there was no deferral for at least one of the studies agreed in the PIP, or after the due date of initiation or completion of a study/measure. The same applies to some regulatory applications for authorised products, as described above. Modification of an Agreed Paediatric Investigation Plan (section 2.3 Opinions on Modification of an agreed PIP, section 3.3 Discussions on Modification of an agreed PIP) The development plan for a medicine can be modified at a later stage as knowledge increases. Modifications can also be made if the applicant encounters such difficulties with the implementation of a PIP, which render it unworkable or no longer appropriate. In some cases, studies can be deferred until after the studies in adults have been conducted. This ensures that research in children is done only when it is safe and ethical to do so. Even when studies are deferred, the PIP will include details of the paediatric studies and their timelines. Class waiver (section 6 Discussion on the applicability of class waiver) As some diseases do not affect children (for example Parkinson's disease), the development of medicines for these diseases should not be performed in children. In these cases, a PIP is not required and it will be waived. For more information on the classes of diseases subject to waivers, see class waivers. Annual reports on deferrals (section 8) If the medicinal product is approved in the EU, annual reports on the deferred measures in the PIP must be submitted to the Agency.
More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/
Paediatric Committee (PDCO) EMA/PDCO/738440/2017
Page 43/43
